# Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

> **NCT01285700** · PHASE2 · UNKNOWN · sponsor: **Zymenex A/S** · enrollment: 10 (actual)

## Conditions studied

- Alpha Mannosidosis

## Interventions

- **DRUG:** Lamazym

## Key facts

- **NCT ID:** NCT01285700
- **Lead sponsor:** Zymenex A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285700, "Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01285700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*